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The uncharged photoactivable probe 2-[3H]diazoflu-
orene ([3H]DAF) was used to examine structural
changes in the Torpedo californica nicotinic acetylcho-
line receptor (AChR) ion channel induced by agonists.
Photoincorporation of [3H]DAF into the AChR consisted
of the following two components: a nonspecific compo-
nent consistent with incorporation into residues situ-
ated at the lipid-protein interface, and a specific compo-
nent, inhibitable by noncompetitive antagonists and
localized to the M2 hydrophobic segments of AChR sub-
units. The nonspecific [3H]DAF incorporation was char-
acterized in the M4 segment of each AChR subunit. The
observed distribution and periodicity of labeled resi-
dues reinforce the conclusion that the M4 segments are
organized as transmembrane a-helices with a common
“face” of each helix in contact with lipid. Within the M2
segments, in the absence of agonist [3H]DAF specifically
labeled homologous residues bVal-261 and dVal-269,
with incorporation into dVal-269 at a 5-fold greater effi-
ciency than into bVal-261. This observation, coupled
with the lack of detectable incorporation into a-M2 in-
cluding the homologous aVal-255, indicates that within
the resting channel [3H]DAF is bound with its photore-
active diazo group oriented toward dVal-269. In the
presence of agonist, there is an ;90% reduction in the
labeling of bVal-261 and dVal-269 accompanied by spe-
cific incorporation into residues (bLeu-257, bAla-258,
dSer-262, and dLeu-265) situated 1 or 2 turns of an a-he-
lix closer to the cytoplasmic end of the M2 segments. The
results provide a further characterization of agonist-
induced rearrangements of the M2 (ion channel) domain
of the AChR.
The nicotinic acetylcholine receptor (AChR)1 isolated from
the electric organ of the marine elasmobranch Torpedo califor-
nica is the best characterized member of a family of ligand-
gated ion channels which includes the g-aminobutyric acid,
glycine, and serotonin 5-HT3 receptors (for recent reviews, see
Refs. 1–3). The AChR is composed of four homologous subunits
(a2bgd) arranged quasi-symmetrically around a central cation-
selective ion channel (4). The subunits each have a character-
istic topology as follows: a large hydrophilic N-terminal domain
containing the agonist binding sites, followed in the primary
structure by three hydrophobic membrane-spanning segments
(M1–M3), a cytoplasmic domain, a fourth hydrophobic trans-
membrane segment (M4), and a short extracellular C-terminal
tail.
Noncompetitive antagonists (NCAs) are agents that block
the AChR permeability response without binding to the agonist
site. These compounds are structurally diverse and include
many aromatic amines but also general anesthetics, steroids,
and even the neuropeptide substance P (reviewed in Ref. 5). A
number of NCAs have been instrumental in identifying regions
of the AChR which contribute to the formation of the pore of the
ion channel. Photoaffinity labeling studies with [3H]chlor-
promazine (6–9) and [3H]triphenylmethylphosphonium (10) as
well as reaction with [3H]meproadifen mustard (11) have all
identified labeled residues within the M2 segments that would
all lie on a common side of an a-helix. These results, in con-
junction with the observed functional properties of AChRs with
mutations in the M2 segments (1, 2), provide the basis for a
model of the ion channel comprised of M2 segments of each
subunit arranged as transmembrane a-helices around the cen-
tral axis, a model consistent with studies of AChR three-dimen-
sional structure derived from electron micrographic image
analysis (4, 12).
The sites of [3H]chlorpromazine, [3H]triphenylmethylphos-
phonium, and [3H]meproadifen mustard incorporation were all
identified in the presence of agonist under conditions where the
AChR is expected to be in the desensitized state. More recently,
3-(trifluoromethyl)-3-(m-[125I]iodo-phenyl)diazirine ([125I]TID),
a small, uncharged photoactivable probe, was used to identify
residues in the channel lining M2 region both in the absence
and presence of agonist, i.e. for AChRs predominantly in the
resting state or desensitized state, respectively (13). [125I]TID
is a potent NCA (14, 15) that reacts nonspecifically with AChR
amino acids in M3 and M4 hydrophobic segments at the lipid-
protein interface (14–17) and specifically with amino acids in
M2 segments of each AChR subunit (13). In the absence of
agonist (resting state), [125I]TID labeled dLeu-265 and dVal-
269 and the homologous residues in the other subunits that are
located 9 and 13 amino acids to the C-terminal side of the
conserved lysine residue at the N terminus of the M2 region
(positions 9 and 13). In the desensitized state, the pattern of
[125I]TID-labeled residues broadened to include homologous
serine residues at positions 2 and 6 (i.e. dSer-258 and dSer-
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262). These results provided the first direct evidence of an
agonist-induced structural rearrangement of the channel lin-
ing M2 helices. They further suggested that in the closed ion
channel the aliphatic residues at positions 9 and 13 form a
permeability barrier to the passage of ions.
To examine further the structure of the channel in different
functional states, we examined the incorporation into the
AChR of another lipophilic photoactivable probe, [3H]diazoflu-
orene ([3H]DAF), both in the absence and presence of agonist.
[3H]DAF has been used to probe the hydrophobic core of eryth-
rocyte membranes (18) as well as the sites of lipid exposure of
Staphylococcus aureus a-toxin (19). Whereas incorporation of
[125I]TID and [3H]DAF both proceed through a UV-induced
reactive carbene, the two compounds are structurally distinct,
and TID produces a singlet carbene (20) whereas DAF produces
a carbene with substantial triplet character (21, 22). We report
here that like [125I]TID, [3H]DAF not only incorporates into
residues situated at the lipid-protein interface but also into
residues in the channel lining M2 segments. We identify the
amino acids within the M4 segments that are labeled nonspe-
cifically as well as the pattern of specific photoincorporation
within the M2 segments. The subunit selectivity of photolabel-
ing within the M2 domain in conjunction with the agonist-de-
pendent redistribution of labeling provide further information
about the change in structure of the AChR ion channel domain
between resting and desensitized states.
EXPERIMENTAL PROCEDURES
Materials—AChR-rich membranes were isolated from T. californica
electric organ (17). 2-[3H]Diazofluorene ([3H]DAF) of specific activities
ranging from 0.67 to 1.4 Ci/mmol was prepared from 2-[3H]fluorenone
according to the procedure described by Pradhan and Lala (18), repu-
rified, and stored at 220 °C in ethanol. [3H]Phencyclidine (43 Ci/mmol)
was from NEN Life Science Products, and [3H]tetracaine (47 Ci/mmol)
was prepared at NEN Life Science Products by catalytic tritiation of
3,3-dibromotetracaine. 1-Azidopyrene was purchased from Molecular
Probes. Carbamylcholine and tetracaine were from Sigma, and phen-
cyclidine (PCP) was from Alltech Associates. L-1-Tosylamido-2-phenyl-
ethyl chloromethyl ketone-treated trypsin was purchased from Worth-
ington and endoproteinase Lys-C from Boehringer Mannheim. Genapol
C-100 (10%) was purchased from Calbiochem. Prestained low molecular
weight gel standards were purchased from Life Technologies, Inc.
Photolabeling AchR-rich Membranes with [3H]DAF—For analytical
labeling experiments, Torpedo membranes (2 mg/ml) in Torpedo phys-
iological saline (TPS, 250 mM NaCl, 5 mM KCl, 3 mM CaCl2, 2 mM
MgCl2, 5 mM sodium phosphate, pH 7.0) were incubated with [
3H]DAF
at a final concentration of 5 mM in the absence or presence of 100 mM
carbamylcholine and in the absence or presence of additional ligands.
After a 30-min incubation, suspensions were irradiated for 5 min at a
distance of less than 1 cm with a 365-nm lamp (EN-Spectroline). Fol-
lowing irradiation, each sample was pelleted (15,000 3 g), the pellet
solubilized in sample loading buffer (23), and then submitted to SDS-
PAGE. Preparative photolabelings (12–15 mg per condition) were car-
ried out at 10 mM [3H]DAF (6100 mM tetracaine) and in the presence of
carbamylcholine (6100 mM phencyclidine). After 1 h incubation, se-
quential photoincorporation of [3H]DAF and then 1-azidopyrene (1-AP)
was carried out as described previously for [125I]TID (17), except that
irradiation of suspensions with 1-AP was limited to 5 min. Samples
were then pelleted and solubilized in electrophoresis sample loading
buffer and submitted to SDS-PAGE.
SDS-Polyacrylamide Gel Electrophoresis—SDS-PAGE was per-
formed as described by Laemmli (23) using either 1.0-mm (analytical)
or 1.5-mm (preparative scale) thick 8% polyacrylamide gels with 0.33%
bis(acrylamide). For analytical gels, polypeptides were visualized by
staining with Coomassie Blue R-250 (0.25% w/v in 45% methanol and
10% acetic acid) and destaining in 25% methanol, 10% acetic acid. The
gels were then impregnated with fluor (Amplify, Amersham Pharmacia
Biotech) for 20 min with rapid shaking, dried, and exposed at 280 °C to
Kodak X-OMAT LS film for various times (3–12 weeks). Incorporation
of 3H into individual polypeptides was quantified by scintillation count-
ing of excised gel pieces as described (24). For preparative scale gels,
polypeptides incorporating 1-AP were visualized from their associated
fluorescence when the gels were illuminated at 365 nm on a UV-light
box. Bands corresponding to AChR subunits were excised, and in some
cases the gel pieces were transferred to the wells of individual 15%
mapping gels (25, 26). Mapping gels were composed of a 4.5% acrylam-
ide stacking gel and a 15% acrylamide separating gel. The gel pieces
were overlaid with 350 ml of buffer (5% sucrose, 125 mM Tris-HCl, 0.1%
SDS, pH 6.8) containing 250 mg of S. aureus V8 protease (500 mg V8
protease for gel pieces containing the a-subunit). Electrophoresis was
carried out overnight at 25 mA constant current. In the course of this
work it was determined that for membranes labeled with 1-AP and
[3H]DAF, the fluorescent- and 3H-labeled-AChR subunits comigrated,
as did their large proteolytic fragments.
1-AP/[3H]DAF-labeled subunits and proteolytic fragments were iso-
lated from the excised gel pieces using a passive elution protocol (17,
27). The eluate was filtered (Whatman No. 1), and the protein was
concentrated using a Centriprep-10 (Amicon). Excess SDS was removed
by acetone precipitation (overnight at 220 °C).
Purification of Proteolytic Digests of [3H]DAF/1-AP-labeled AChR
Subunits to Isolate Fragments Containing the M2 Segment—For trypsin
digestion, acetone-precipitated subunits (b and d) were resuspended in
a small volume (;50 ml) of buffer (100 mM NH4HCO3, 0.1% SDS, pH
7.8). The SDS concentration was then reduced by diluting with buffer
without SDS, and Genapol C-100 was added, resulting in final concen-
trations of 0.02% SDS, 0.5% Genapol C-100, and 1–2 mg/ml protein.
Trypsin was added to a 1:5 (w/w) enzyme to substrate ratio and incu-
bated at room temperature for 4 days. For endoproteinase Lys-C (EKC)
digestion, subunits (a) were resuspended in 15 mM Tris-HCl, 0.1% SDS,
pH 8.1, at 1–2 mg/ml protein. Approximately 1.5 units of EKC was
added and incubated at room temperature for 6 days. Both trypsin and
EKC digests were separated on Tricine/SDS-polyacrylamide gels pre-
pared as described (17, 28). Aliquots of each of the digests (;5%) were
routinely resolved on analytical scale Tricine/SDS-polyacrylamide gels
(1.0-mm thick) along with prestained molecular weight standards (Life
Technologies, Inc.) as follows: ovalbumin (43,000), carbonic anhydrase
(29,000), a-lactoglobulin (18, 400), lysozyme (14, 300), bovine trypsin
inhibitor (6, 200), the A chain of insulin (3, 400), and the B chain of
insulin (2, 300). Analytical gels were soaked in 25% methanol, 10%
acetic acid for 30 min, and then prepared for fluorography.
For each of the AChR subunits labeled under a given condition, the
bulk of the proteolytically digested material was resolved on individual
1.5-mm thick Tricine/SDS-polyacrylamide gels. Proteolytic fragments
containing the M2 region of each of the AChR subunits were identified
and isolated using two different sets of criteria. First, for digestion
conditions nearly identical to those employed here, it had been deter-
mined previously where proteolytic fragments containing the M2 seg-
ments migrate relative to Life Technologies, Inc., pre-stained molecular
weight standards (11, 13). Second, proteolytic fragments were selected
which begin at the N termini of the M2 segments and extend through
M3 hydrophobic segments. Incorporation of 1-AP into the M3 segments
(17) could then be used to visualize the M2-M3 fragment by illuminat-
ing the Tricine/SDS-polyacrylamide gel at 365 nm on a UV-light box.
Finally, aliquots of each of the digests were resolved on analytical
Tricine/SDS-polyacrylamide gels, and some time later, fluorographs of
those gels were used to confirm that [3H]DAF was indeed incorporated
into these bands.
1-AP/[3H]DAF-labeled fragments were further purified by reversed-
phase HPLC using a Brownlee Aquapore C4 column (100 3 2.1 mm) as
described (17). Solvent A was 0.08% trifluoroacetic acid in water; sol-
vent B was 0.05% trifluoroacetic acid in 60% acetonitrile, 40% 2-propa-
nol, and the elution gradient was from 25 to 100% solvent B in 80 min.
The elution of peptides was monitored by the absorbance at 210 nm and
by fluorescence emission (357 nm excitation, 432 nm emission). The
elution of [3H]DAF was monitored by scintillation counting of an aliquot
(25 ml) of each fraction.
Generation and Isolation of Fragments of AChR Subunits Containing
[3H]DAF/1-AP-labeled M4 Segments—Fragments beginning near the
N terminus of the M4 segment of each AChR subunit were isolated as
described (17) for [125I]TID/1-AP-labeled subunits. Briefly, in gel diges-
tion of each isolated subunit with S. aureus V8 protease was used to
generate 10–14-kDa subunit fragments as follows: aV8–10 (aAsn-339
to aGly-437); bV8–12 (bMet-384/bSer-417 to bAla-469); gV8–14 (gLeu-
373/gIle-413 to gPro-489; dV8–11 (Lys-d436 to dAla-501). Trypsin di-
gests of these fragments were fractionated by Tricine/SDS-PAGE yield-
ing fluorescent and 3H containing bands of 3–4 kDa for a-subunit
(aT-4K), 5 kDa for b- and g-subunits (bT-5K and gT-5K), and 6 kDa for
d-subunit (dT-6K). Material eluted from these bands was further puri-
fied by reversed-phase HPLC. With the exception of the d-subunit
digest, each digest yielded a single major peak of 3H which coeluted
with 1-AP fluorescence, and these peaks eluted at the same concentra-
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tions of organic solvent as had been seen for the [125I]TID/1-AP-labeled
M4 segments. Material in these fractions were pooled, dried, and re-
suspended for protein microsequence analysis. The tryptic digest of
dT-6K yielded a broader distribution of 3H without significant fluores-
cence, and material was pooled from the concentrations of organic
eluent that had been found to contain [125I]TID/1-AP-labeled dM4.
Sequence Analysis—N-terminal sequence analysis was performed on
an Applied Biosystems model 477A protein sequencer using gas phase
cycles. Pooled HPLC samples were dried by vacuum centrifugation,
resuspended in a small volume of 0.05% SDS (;20 ml), and immobilized
on chemically modified glass fiber disks (Beckman Instruments). Ap-
proximately 30% of the released PTH-derivatives were separated by an
on-line Model 120A PTH-derivative analyzer, and approximately 60%
was collected for determination of released 3H by scintillation counting
of each sample for three 5-min intervals. Initial yield (I0) and repetitive
yield (R) were calculated by nonlinear least squares regression of the
observed release (M) for each cycle (n): M 5 I0R
n (PTH-derivatives of
Ser, Thr, Cys, and His were omitted from the fit).
Radioligand Binding Assays—The equilibrium binding of [3H]PCP (6
nM), [3H]tetracaine (2 nM), and [3H]histrionicotoxin (10 nM) to Torpedo
membranes was assayed by centrifugation. 500-ml aliquots of mem-
brane suspensions (0.5 mg of protein/ml in TPS, ;0.6 mM AChR) were
equilibrated with the radioligand and the nonradioactive cholinergic
ligands for 2–3 h in 10 3 75-mm Pyrex disposable culture tubes (Corn-
ing) and then transferred to 1.5-ml plastic microcentrifuge tubes and
pelleted for 45 min at 15,000 rpm in a Sorvall SA-600 rotor. After
removal of the supernatants, the membrane pellets were solubilized in
100 ml of 10% SDS, and the pellet 3H was determined by liquid scintil-
lation counting.
RESULTS
In initial experiments, nonradioactive DAF (Fig. 1) was
tested as an inhibitor of the equilibrium binding of radiola-
beled, positively charged AChR NCAs. [3H]Tetracaine binds
with high affinity (Keq 5 0.3 mM) in the absence of agonist to one
site per AChR monomer, whereas it binds ;100-fold more
weakly to desensitized AChRs (29). The sites of specific photo-
incorporation of [3H]tetracaine are restricted to amino acids
within each M2 segment (30). In the absence of agonist, DAF
produced a dose-dependent inhibition of [3H]tetracaine binding
(IC50 5 6 mM), with high concentrations inhibiting ;60% of
specific binding2 (Fig. 1A). For desensitized AChRs, [3H]phen-
cyclidine binds with high affinity (Keq 5 1 mM) to a single site
per AChR (31), and DAF also acted as an allosteric inhibitor of
[3H]phencyclidine binding (Fig. 1B, IC50 5 10 mM, 60% maxi-
mal inhibition). DAF also acted as an allosteric inhibitor of
[3H]histrionicotoxin binding, with IC50 5 2 mM and maximal
inhibition of 50% in the presence of agonist (data not shown).
Initial photolabeling experiments were designed to charac-
terize the general pattern of [3H]DAF photoincorporation into
Torpedo AChR-rich membranes as well as to test the sensitiv-
ity of the photoincorporation to cholinergic ligands. Membranes
(2 mg/ml) were equilibrated with 5 mM [3H]DAF in the absence
and in the presence of 100 mM carbamylcholine. After irradia-
tion, membrane suspensions were pelleted and resuspended in
electrophoresis sample buffer, and the pattern of incorporation
was monitored by SDS-PAGE followed by fluorography. As is
evident in the fluorograph of an 8% polyacrylamide gel (Fig. 2,
lanes 3 and 4), there was appreciable incorporation of [3H]DAF
into each of the AChR subunits. Neither the overall labeling
pattern nor the relative incorporation into individual AChR
subunits was affected by the inclusion of 100 mM carbamylcho-
line (Fig. 2, lane 4). Based on liquid scintillation counting of
excised gel bands, ;1% of subunits incorporated 3H, with ap-
proximately equal incorporation in each subunit (a/b/g/d:
1/(0.8 6 0.2)/(0.93 6 0.3)/(1.2 6 0.3)). The presence of carba-
2 Although high concentrations of DAF were apparently unable to
fully displace [3H]PCP or [3H]tetracaine, further studies are required to
determine whether this reflects a true allosteric inhibition or the lim-
ited aqueous solubility of DAF.
FIG. 1. Effects of diazofluorene on the binding of [3H]tetra-
caine and [3H]PCP in the absence and in the presence of carba-
mylcholine, respectively. AChR-rich membranes (0.5 mg/ml, 0.60 mM
ACh binding sites) containing 2 nM [3H]tetracaine (A) or 6 nM [3H]PCP
and 200 mM carbamylcholine (B) were equilibrated for 2–3 h with
increasing concentrations of diazofluorene (DAF). Bound tritiated li-
gand (f) was determined by centrifugation (“Experimental Proce-
dures”). In each panel the dashed line indicates nonspecific bound
tritiated ligand in the presence of 200 mM tetracaine (A, M) or meproa-
difen (B, M) at 0 and 500 mM DAF.
FIG. 2. Photoincorporation of [3H]DAF into AChR-rich mem-
branes in the absence and presence of carbamylcholine. AChR-
rich membranes were equilibrated with [3H]DAF (5 mM) in the absence
(lanes 1 and 3) and in the presence (lanes 2 and 4) of 100 mM carbamyl-
choline and irradiated at 365 nm for 5 min. Polypeptides were resolved
by SDS-PAGE, visualized by Coomassie Blue stain (lanes 1 and 2), and
processed for fluorography (4-week exposure; lanes 3 and 4). Labeled
lipid and free photolysis products were electrophoresed from the gel
with the tracking dye. The AChR subunits and the Na1/K1 ATPase
a-subunit (aNK) are indicated. In addition, bands of 89 (89K), 37 (37K),
34 (34K), and 32 (32K) kDas are also indicated. These bands have been
identified by N-terminal sequence analysis of purified proteolytic frag-
ments to be the chloride channel CLC-0, calectrin (annexin V), the
mitochondrial voltage-dependent anion channel, and the mitochondrial
ATP/ADP translocase, respectively. The AChR-associated 43-kDa pro-
tein is not indicated but can be seen migrating with a slightly slower
mobility than the AChR a-subunit (lanes 1 and 2). Also not indicated is
a 105-kDa band that can be seen migrating with slightly slower mobil-
ity than the a-subunit of the Na1/K1 ATPase.
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mylcholine resulted in a ,10% change of subunit labeling.
Incorporation of [3H]DAF into the AChR subunits accounted
for approximately 60% of the total labeling in polypeptides
present in Torpedo AChR-rich membranes.
Two NCAs, tetracaine and proadifen, were tested at concen-
trations of 3, 30, and 250 mM for their effects on [3H]DAF
photoincorporation into AChR-rich membranes in the absence
and in the presence of 100 mM carbamylcholine, respectively.
The effects of these ligands on [3H]DAF (5 mM) photoincorpo-
ration was examined by fluorography and by liquid scintilla-
tion counting of excised gel pieces. The pattern of incorporation
was qualitatively very similar in each of the different condi-
tions, with a small dose-dependent decrease (;15–25%) in the
labeling of the subunits evident for both tetracaine and proa-
difen that was not seen for other labeled non-AChR polypep-
tides (data not shown). The relative distribution of 3H incorpo-
ration within the a-subunit was examined by determining 3H
incorporation within the four large, non-overlapping a-subunit
fragments that can be generated by digestion with S. aureus V8
protease (14, 26). Inspection of the fluorograph of the dried
mapping gel indicated that all the visible labeling was con-
tained within a 20-kDa fragment (aV8–20, Ser-173–Glu-338)
containing hydrophobic segments M1–M3 and a 10-kDa frag-
ment (aV8–10, Asn-339–Gly-437) containing the M4 segment.
Based on liquid scintillation counting of the excised gel pieces,
75% of 3H cpm was incorporated in aV8–10 and 25% was in
aV8–20, with the relative incorporation of [3H]DAF into
aV8–10 similar for labelings carried out in the absence (77%)
and in the presence (74%) of 100 mM carbamylcholine.
Sites of [3H]DAF Incorporation in M4 Segments of Each
AChR Subunit—The M4 segments were isolated from tryptic
digests of large V8-protease fragments of each of the receptor
subunits as described under “Experimental Procedures.” For
a-subunit, tryptic digestion of aV8–10 produced a fluorescent
and radioactive band of 3–4 kDa (aT-4K), which was further
purified by reversed-phase HPLC. N-terminal sequence analy-
sis (Fig. 3A) revealed the presence of a single sequence begin-
ning at aTyr-401 (490 pmol) that was present in a 10–20-fold
greater abundance than any secondary sequence. The largest
release of 3H occurred in cycle 12, with additional release in
cycles 8, 15, and 18. The same pattern of 3H release was seen
for the M4 segment isolated from membranes labeled in the
presence of 100 mM carbamylcholine (data not shown). 3H re-
lease in cycle 12 indicated that aCys-412 was the primary site
of incorporation of [3H]DAF in aM4, as it was for [125I]TID (17),
with lower level reaction with aHis-408, aMet-415, and
aCys-418.
Tryptic digestion of bV8–12 produced a fluorescent and ra-
dioactive band migrating with an apparent molecular mass of 5
kDa (bT-5K) on a Tricine/SDS-polyacrylamide gel which was
further purified by HPLC. As shown in Fig. 3B, sequence
analysis of this material revealed the presence of a primary
sequence beginning at bAsp-427 (84 pmol), as well as a second-
ary sequence beginning at Tyr-401 of the a-subunit (24 pmol).3
3 The presence of a contaminating a-subunit fragment in b-subunit
fractions occurred uniquely in the particular experiment in Fig. 3B.
Since a-subunit does not contaminate b-subunit preparations in detect-
able quantities, the contamination in this sample most likely resulted
when the reversed-phase HPLC column was washed insufficiently be-
tween the purification of the a-subunit T-4K fragment and the purifi-
cation of the b-subunit T-5K band. Based upon an estimated 8.6 pmol of
aCys-412 in cycle 12 of the b-subunit sample (Fig. 3B, calculated from
FIG. 3. Radioactivity and mass release upon sequential Edman degradation of [3H]DAF/1-AP-labeled fragments containing the M4
segment. A, a-subunit tryptic peptide T-4K isolated by HPLC from membranes labeled with 5 mM [3H]DAF (18,800 cpm loaded on the filter and
3,770 cpm remaining after 29 cycles). The only sequence detected began at aTyr-401 (I0, 490 pmol; R, 90%). B, b-subunit tryptic peptide T-5K
isolated by HPLC (3,480 cpm loaded on the filter and 591 cpm remaining after 29 cycles). The primary sequence began at bAsn-427 before M4 (I0,
85 pmol; R, 95%), with a secondary sequence beginning at aTyr-401 before a-M4 (I0, 24 pmol; R, 91% (see text
3)). C, g-subunit tryptic fragment
T-5K isolated by HPLC (3,680 cpm loaded on the filter and 669 cpm remaining after 27 cycles). The only sequence detected began at gVal-446 (I0,
110 pmol; R, 91%). D, d-subunit tryptic peptide T-6K isolated by HPLC (1,660 cpm loaded on the filter and 290 cpm remaining after 24 cycles). The
only sequence detected began at dLeu-456 (I0, 49 pmol; R, 95%). For each sample 60% of each cycle of Edman degradation was analyzed for released
3H (l) and 30% for PTH-derivatives (M), with the dashed lines corresponding to the exponential decay fit of the amount of detected PTH-derivatives
for the peptides containing M4. The amino acid sequence of the sequenced peptide containing the M4 region is shown above each panel, with the
solid line indicating the limits of the M4 regions.
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The largest 3H release occurred in cycle 15, with additional
release in cycles 12 and 21 and a “shoulder” of release in cycles
17 and 18. The amount of aTyr-401 peptide present was clearly
insufficient to account for the release in cycles 15, 17, 18, and
21, although it did account3 for the release in cycle 12. There-
fore, a comparison of the pattern of 3H release with the corre-
sponding amino acids identified in the peptide beginning at
bAsp-427 indicate that Tyr-441 is the primary site of labeling,
with additional reaction with Phe-443, Phe-444, and Cys-447.
When the M4 region was isolated from membranes labeled in
the presence of 100 mM carbamylcholine and the purified ma-
terial then subjected to sequence analysis, a single sequence
was detected beginning at bAsp-427 (34 pmol) and the same
four residues were found to be labeled, with no release detected
in cycle 12.
When the tryptic digest of gV8–14 was resolved on a Tricine/
SDS-polyacrylamide gel, a band of fluorescence and 3H mi-
grated with an apparent molecular mass of 5 kDa (gT-5K)
which was eluted and further purified by reversed-phase
HPLC. Sequence analysis (Fig. 3C) revealed the presence of a
single sequence beginning at gVal-446 and extending through
gM4 (112 pmol), with 3H release in cycles 6 and 8 consistent
with [3H]DAF incorporation into gCys-451 and gTrp-453
within g-M4. 3H incorporation into these two residues was also
seen in the N-terminal sequence analysis of gT-5K isolated
from membranes labeled in the presence of carbamylcholine
(not shown).
The tryptic digest of dV8–11 produced a faint band of fluo-
rescence and 3H which migrated with an apparent molecular
mass of 6 kDa (dT-6K). The HPLC elution profile of the mate-
rial isolated from the dT-6K band exhibited a broad and com-
plex distribution of 3H which included a peak eluting at the
concentration of organic solvent characteristic of the elution of
[125I]TID-labeled d-M4 (17). Sequence analysis of this material
(Fig. 3D) established the presence of a single sequence begin-
ning at dLeu-456 (49 pmol). Thus, for dV8–11, trypsin cleaved
after Arg-455 at the beginning of M4, even though for the
corresponding g-subunit fragment efficient cleavage occurred
not at the corresponding gLys-449 but at the preceding gLys-
445. No clear 3H release was detected above the general
washoff of 3H in the early cycles, although there was very small
release of 3H (5 cpm) detected in cycles 3 and 4 corresponding
to dMet-458 and dPhe-459. Similar low level release (8 cpm)
was also detected in cycle 4, with no release above background
in cycle 3, when this d-M4 peptide was isolated in another
experiment from membranes labeled in the presence of 100 mM
carbamylcholine.
[3H]DAF Labeling in the Ion Channel—To determine the
sites, the agonist sensitivity, and the specificity of [3H]DAF
photoincorporation in the M2 regions of AChR subunits, T.
californica AChR-rich membranes (;1.4 mM AChR) were pho-
tolabeled with 10 mM [3H]DAF under four different conditions
as follows: 1) in the absence of agonist; 2) in the absence of
agonist and in the presence of 100 mM tetracaine; 3) in the
presence of 100 mM carbamylcholine; 4) in the presence of 100
mM carbamylcholine and in the presence of 100 mM phencyclid-
ine (PCP).
Identification of the Sites of [3H]DAF Incorporation in
d-M2—The d-subunits isolated from AChRs labeled with
[3H]DAF under the four different conditions (;300 mg/condi-
tion) were digested with 20% (w/w) trypsin for 4 days. The
digests were resolved by Tricine/SDS-PAGE, and a 5.1-kDa
fragment (dT-5.1K; Fig. 4), known to contain the M2-M3 region
(13), was isolated from the gel as described under “Experimen-
tal Procedures.” The material eluted from the dT-5.1K band
was further purified by reversed-phase HPLC (Fig. 5), and for
each labeling condition, the majority of 3H counts eluted in a
peak centered at 74% solvent B. HPLC fractions 29–31 were
pooled and sequenced (Fig. 6). For each of the labeling condi-
tions, a single sequence was evident beginning at dMet-257 at
the N terminus of d-M2. In addition, each of the samples
sequenced with similar efficiencies and mass levels (see legend
to Fig. 6). For dT-5.1K labeled in the absence of agonist, 3H
release occurred primarily in cycle 13 (Fig. 6A (l)), a result
that indicates that the labeled amino acid is dVal-269 (26
cpm/pmol) in d-M2. For the 3H release profile of dT-5.1K la-
beled in the absence of agonist but in the presence of 100 mM
tetracaine (E, Fig. 6A), there was an approximately 90% reduc-
tion in [3H]DAF incorporation into dVal-269 (3 cpm/pmol). The
presence of agonist alone (Fig. 6B, l) caused a similar reduc-
tion in 3H incorporation into dVal-269 (2 cpm/pmol), and there
the mass of the aTyr-401 peptide) and the amount of [3H]DAF incorpo-
ration into aCys-412 (;4 cpm/pmol, Fig. 3A (cycle 12)), the 8 cpm
release in cycle 12 of Fig. 3B must result from the a-subunit fragment.
In contrast, the 3H release in cycles 15, 17, 18, and 21 cannot result
from the aTyr-401 peptide.
FIG. 4. Trypsin digestion of d-subunit from AChR photolabeled
with [3H]DAF in the presence and absence of carbamylcholine
(Carb) and noncompetitive antagonists. d-Subunits, isolated from
AChR-rich membranes labeled with [3H]DAF under the four different
conditions indicated (top), were digested with 20% (w/w) trypsin for 4
days. Aliquots of the digests (;5%) were fractionated by Tricine/SDS-
PAGE and then subjected to fluorography for 8 weeks. The migration of
prestained molecular weight standards are indicated on the right, and
the relative molecular masses of the principal [3H]DAF-labeled diges-
tion products are shown on the left. The dT-5.1K band contains a fragment
beginning at dMet-257 before M2 and extending through M3. The dT-3.1K
fragment contains the M2 region alone, N terminus: dMet-257.
FIG. 5. Reversed-phase HPLC purification of [3H]DAF-labeled
tryptic fragment dT-5.1K. dT-5.1K isolated from tryptic digests of
AChR d-subunits (Fig. 4) was further purified by reversed-phase HPLC
as described under “Experimental Procedures.” The elution of [3H]DAF-
labeled peptides was determined by scintillation counting of aliquots
(25 ml) of the collected fractions (l, E). Elution profiles are shown for
dT-5.1K material labeled in the absence of agonist but in the absence
(l) or presence (E) of 100 mM tetracaine. Based upon the recovery of
radioactivity, for each of the samples .90% of the material was recov-
ered from the HPLC column.
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was also a small but significant release of 3H in cycles 6 and 9
that corresponds to [3H]DAF incorporation into dSer-262 (1.9
cpm/pmol) and dLeu-265 (1.3 cpm/pmol) with similar efficiency
as in dVal-269. Finally, in the presence of both agonist and 100
mM PCP, there was no detectable 3H release in cycles 6 and 9,
whereas release in cycle 13 was unaffected (Fig. 6B, E).
In addition to dT-5.1K, sites of [3H]DAF incorporation in
d-M2 were also revealed from the sequence analysis of d-sub-
unit tryptic fragments of 3.1 kDa (d-T-3.1K; Fig. 4) and 7.4 kDa
(data not shown). When purified by HPLC, the peak of 3H for
dT-3.1K (labeled in the absence of agonist) eluted earlier from
the reversed-phase HPLC column (fractions 22–24) than did
dT-5.1K. Sequence analysis revealed the presence of a primary
sequence beginning at dMet-257 with a major site of 3H release
in cycle 13 (dVal-269). The molecular mass of dT-3.1K as well as
its early elution from the reversed-phase column (52% organic)
are consistent with this fragment containing the M2 but not
the M3 region (i.e. Met-257–Arg-277). Identical amino termini
(dMet-257) and 3H release profile were observed upon sequenc-
ing dT-7.4K (HPLC fractions 29–31). These results not only
confirm that dVal-269 is the site of incorporation of [3H]DAF in
dM2, they also confirm that both the labeled and unlabeled
peptides are copurifying. This latter result is consistent with
similar results observed using several different ligands and
nearly identical purification steps (11, 13, 32).
Identification of the Sites of [3H]DAF Incorporation in
b-M2—In a manner similar to that for d-subunit, the sites of
[3H]DAF photoincorporation in the M2 region of b-subunit
were determined by digesting the subunit (;250 mg/labeling
condition) with 20% (w/w) trypsin for 4 days. The digests from
each of the four labeling conditions were then fractionated by
Tricine/SDS-PAGE and a 7.2-kDa band (bT-7.2K), known to
contain the M2–M3 region (13), was isolated (see under “Ex-
perimental Procedures”). When the gels were illuminated at
365 nm on a UV-light box, the bT-7.2K fragment, which mi-
grates as a sharp band of 3H in the fluorograph of an analytical
Tricine/SDS-PAGE gel, migrated in an area of weak fluores-
cence between two strongly fluorescent bands of 10 and 5.5
kDas (data not shown). The material eluted from the bT-7.2K
fragment was further purified by reversed-phase HPLC (Fig.
7), and for each labeling condition the majority of 3H counts
eluted in a peak centered at 84% solvent B. HPLC fractions
29–33 were pooled and sequenced (Fig. 8). In each of the four
labeling conditions, sequence analysis revealed the presence of
a single peptide beginning at bMet-249 at the N terminus of
bM2 that was sequenced at similar efficiency and mass level for
each sample (see legend to Fig. 8). For the sample labeled in the
absence of any ligands other than [3H]DAF itself, the major
release of 3H release was in cycle 13, with lower release in cycle
9 (l, Fig. 8A). This pattern of release corresponds to [3H]DAF
incorporation into bLeu-257 (0.7 cpm/pmol) and bVal-261 (5.3
cpm/pmol) within b-M2. The presence of tetracaine (E, Fig. 8A)
resulted in an approximately 95% reduction in the incorpora-
tion into bVal-261 (0.2 cpm/pmol). The addition of agonist (l,
Fig. 8B) resulted in a substantial reduction in the amount of
[3H]DAF incorporated into bVal-261, although the extent of
inhibition was difficult to quantify because that reduced re-
lease in cycle 13 was associated with a dramatic increase in 3H
release in cycles 9 and 10 that corresponds to increased incor-
poration of [3H]DAF into bLeu-257 (2 cpm/pmol) and bAla-258
(;3 cpm/pmol). Interestingly, the presence of excess PCP (E,
Fig. 8B) resulted in an 80% reduction in the amount of incor-
poration into bLeu-257 (0.4 cpm/pmol) but only a 50% reduc-
tion in the labeling of bAla-258 (1.5 cpm/pmol).
Identification of the Sites of [3H]DAF Incorporation in
a-M2—The a-subunits isolated from AChRs labeled under each
of the four different conditions (;500 mg of a-subunit/labeling
condition) were each digested with 1.5 units of endoproteinase
Lys-C for 6 days. The digests were then resolved by Tricine/
FIG. 6. Radioactivity and mass release upon N-terminal sequence analysis of d-T-5.1K. d-T-5.1K was isolated by Tricine/SDS-PAGE
followed by reversed-phase HPLC (Fig. 5) and then subjected to automated Edman degradation, with 60% of each cycle analyzed for released 3H
(l, E) and 30% for PTH-derivatives (M, with the dashed lines corresponding to the exponential decay fit of the amount of detected PTH-
derivatives). The amino acid sequence of the sequenced peptide containing the M2 region is shown above each panel. A, 3H release from dT-5.1K
labeled in the absence of agonist (l, 2/2), or in the absence of agonist but in the presence of 100 mM tetracaine (E, 2/1). 2/2: I0 5 47 pmol; R 5
93%; 15,000 cpm loaded/5,000 cpm remaining on filter. 2/1: I0 5 38 pmol; R 5 94%; 9,000 cpm loaded/3,200 cpm remaining. B,
3H release from
dT-5.1K labeled in the presence of agonist (l, 1/2) or in the presence of agonist and in the presence of 100 mM PCP (E, 1/1). 1/2: I0 5 51 pmol;
R 5 93%; 13,700 cpm loaded/3,900 cpm remaining. 1/1: I0 5 57 pmol; R 5 93%; 13,000 cpm loaded/3,500 cpm remaining.
FIG. 7. Reversed-phase HPLC purification of [3H]DAF-labeled
tryptic fragment bT-7.2K. A 7.2-kDa molecular mass fragment iso-
lated by Tricine/SDS-PAGE from tryptic digests of AChR b-subunit
labeled under four different conditions material was then further puri-
fied by reversed-phase HPLC (see “Experimental Procedures”). The
elution of [3H]DAF-labeled peptides was determined by scintillation
counting of aliquots (25 ml) of the collected fractions (l, E). Elution
profiles are shown for bT-7.2K material labeled in the absence of ago-
nist but in the absence (l) or presence (E) of 100 mM tetracaine. Based
upon the recovery of radioactivity, for each of the samples .90% of the
material was recovered from the HPLC column.
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SDS-PAGE, and an approximately 10-kDa band (aK-10K), pre-
viously shown to contain the M2-M3 region (11), was excised
(see “Experimental Procedures”). Inspection of the fluorogram
of the gel of the analytical digests (Fig. 9) revealed that the
aK-10K fragment migrated with lower mobility than the major
radiolabeled band of 7.8 kDa that was also intensely fluores-
cent (not shown). When the material eluted from the aK-10K
band was further purified by reversed-phase HPLC, for each
labeling condition the majority of 3H counts were in a peak
centered at 78% solvent B. HPLC fractions 31–34 were pooled
and sequenced (Fig. 10). For each sample the primary sequence
began at aMet-243 before a-M2 (;25 pmol), and a secondary
sequence beginning at aTyr-401 before M4 was present at ;8
pmol.4 For all four of the samples, which correspond to each of
the different labeling conditions, low level 3H release was seen
in cycles 12, 15, and 18. This pattern of release corresponds to
that observed for nonspecific [3H]DAF incorporation into a-M4
region, i.e. labeling of aCys-412, aMet-415, and aCys-418 (Fig.
3A).4 For both of the a-K-10K samples labeled in the absence of
agonist (with and without tetracaine), no other sites of 3H
release were evident (Fig. 10), a result that indicates that
[3H]DAF does not incorporate into a-M2. Had [3H]DAF incor-
porated into aVal-255 in a-M2 at the same efficiency as it did
into dVal-269, release of 180 cpm would be observed in cycle 13.
For the aK-10K sample isolated from AChRs labeled in the
presence of agonist, there was also 3H release in cycles 6 and 9
at levels similar to cycle 12 (data not shown) that was elimi-
nated (cycle 6) by the presence of PCP. Thus, in the presence of
agonist there was low level labeling (;1 cpm/pmol) of aSer-248
and aLeu-251 as was seen for the equivalent amino acids in
d-M2 (Fig. 6B).
DISCUSSION
The results presented here demonstrate that the uncharged
hydrophobic compound 2-[3H]diazofluorene ([3H]DAF) photoin-
corporates in a specific and agonist-sensitive fashion into res-
idues in the channel lining M2 region of the nicotinic AChR. In
addition, [3H]DAF photoincorporates in a agonist-insensitive
manner into the M4 segment of each receptor subunit. There-
fore, there exist two components to the labeling of the AChR by
[3H]DAF as follows: a nonspecific component consistent with
incorporation into residues situated at the lipid-protein inter-
face of the AChR, and a specific component, inhibitable by
noncompetitive antagonists, sensitive to state-dependent tran-
sitions, and localized to residues within the ion channel. It is
significant that even in the absence of agonist the specific
photoincorporation of [3H]DAF within d- or b-M2 can be clearly
revealed only during N-terminal sequence analyses of isolated
peptides, since that component of the photolabeling is #20% of
the total labeling at the level of isolated subunits or even of
proteolytic fragments after fractionation by SDS-PAGE and
reversed-phase HPLC (Figs. 5 and 7). Unlike [125I]TID at mi-
cromolar concentrations for which the reaction with residues
within M2 segments comprises 70% of the total labeling at the
subunit level, for [3H]DAF at micromolar concentrations label-
ing of d-M2 does not predominate over labeling of residues in
the M4 segments. For example, for M2 and M4 segments iso-
lated from the same labeling experiment, the inhibitable 3H
incorporation in dVal-269 (7–8 cpm/pmol) is ;twice the level of
nonspecific labeling in aCys-412 (3–4 cpm/pmol), the most
4 Fragments containing a-M4 beginning at aTyr-401 and aSer-388
were found to be present at higher mass levels (40 pmol) in the material
purified from the intensely fluorescent, radiolabeled 7.8-kDa fragment
(aK-7.8K). Based upon the mass level of the aTyr-401 peptide in the
aK-10K band (Fig. 10A), the 3H release in cycle 12 would correspond to
labeling of aCys-412 in M4 at a level (9 cpm/pmol) similar to that seen
for labeling of aCys-412 (8 cpm/pmol) in the sequence analysis of the
aK-7.8K band.
FIG. 8. Radioactivity and mass release upon N-terminal sequence analysis of b-T-7.2K. bT-7.2K was isolated by Tricine/SDS-PAGE
followed by reversed-phase HPLC (Fig. 7) and then subjected to automated Edman degradation with 60% of each cycle analyzed for released 3H
(l, E) and 30% for PTH-derivatives (M, with the dashed lines corresponding to the exponential decay fit of the amount of detected PTH-derivatives
for the peptides containing M2). The amino acid sequence of the sequenced peptide containing the M2 region is shown above each panel. A, 3H
release from bT-7.2K labeled in the absence of agonist but in the absence (l, 2/2) or presence (E, 2/1) of 100 mM tetracaine. 2/2: I0 5 63 pmol;
R 5 88%; 9,200 cpm loaded/2,000 remaining on filter; 2/1: I0 5 61 pmol; R 5 92%; 7,200 cpm loaded/1,400 cpm remaining). B,
3H release from
bT-7.2K labeled in the presence of agonist but in the absence (l, 1/2) or presence of 100 mM PCP (E, 1/1). 1/2: I0 5 70 pmol; R 5 90%; 10,800
cpm loaded/2,400 cpm remaining. (1/1: I0 5 70 pmol; R 5 90%; 9,600 cpm loaded/2,900 cpm remaining.)
FIG. 9. Endoproteinase Lys-C digestion of a-subunit from
AChRs photolabeled with [3H]DAF in the presence and absence
of carbamylcholine and noncompetitive antagonists. a-Subunit,
which was isolated from AChR-rich membranes labeled with [3H]DAF
under the four different conditions indicated (top), was digested with
1.5 units of endoproteinase Lys-C for 6 days. Aliquots of the digests
(;5%) were fractionated by Tricine/SDS-PAGE and then subjected to
fluorography for 6 weeks. The migration of prestained molecular weight
standards are indicated on the right and the relative molecular masses
of the principal [3H]DAF-labeled digestion products are shown on the
left. The aK-7.8K fragment contained the M4 region, amino termini:
aSer-388, aTyr-401. The aK-10K fragment contained a peptide begin-
ning at aMet-243 before M2 and a peptide beginning at aTyr-401 before
M4 (see Fig. 10).
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highly labeled residue in M4.
Characterization of [3H]DAF Labeling at the Lipid-Protein
Interface—The majority of AChR labeling by [3H]DAF appears
similar to the component of [125I]TID labeling which is inhib-
itable neither by agonist nor by an excess of non-radioactive
TID and which is consistent with photoincorporation into lipid-
exposed regions of the AChR (14–17). [3H]DAF incorporation
into each AChR subunit M4 segment was determined under
labeling conditions done in the absence and in the presence of
100 mM carbamylcholine. In either condition [3H]DAF reacted
in a-M4 with His-408, Cys-412, Met-415, and Cys-418 (Fig. 3A);
in b-M4 with Tyr-441, Phe-443, Phe-444, and Cys-447 (Fig.
3B); in g-M4 with Cys-451 and Trp-453 (Fig. 3C). The low level
of 3H release within d-M4 allows only a tentative assignment
for Met-458 (Fig. 3D). Although the isolation of M4 fragments
by alternative digestion strategies would provide unambiguous
proof that the observed 3H release originates from the observed
M4 peptides, this is the expected result based upon previous
studies with [125I]TID that establish that the labeled and un-
labeled peptides coelute from the reversed-phase column (16,
17). It is also important to point out that due to the lags
resulting from the ;90% repetitive yields inherent in the Ed-
man degradation reaction, cycles that follow a labeled amino
acid also contain prior PTH-derivatives and associated 3H. It is
therefore difficult to detect the presence of labeled amino acids
which immediately follow another labeled amino acid, particu-
larly if the efficiency of incorporation into those residues is
significantly lower. Without direct characterization of the 3H-
labeled amino acids released in each cycle, one cannot deter-
mine whether some of the 3H release in cycles immediately
following these labeled residues is due to amino acids which
have also reacted with [3H]DAF.
Residues incorporating [3H]DAF are summarized in Fig. 11
where M4 segments are modeled as a-helices and residues
previously shown to react with [125I]TID (17) are indicated with
an asterisk. Both [125I]TID and [3H]DAF are hydrophobic com-
pounds that partition efficiently into Torpedo membranes. In
addition, both compounds incorporate via a UV-induced reac-
tive carbene. It is therefore not surprising that many of the
same residues in the M4 regions of each of the AChR subunits
are labeled by both compounds. However, each of these com-
pounds is structurally as well as photochemically unique, with
TID forming a singlet carbene (20) and DAF a carbene with
substantial triplet character (21, 22). Interestingly, aHis-408,
bPhe-443, and gTrp-453 are labeled by [3H]DAF but not
[125I]TID. As previously noted for the labeling pattern of
[125I]TID (17), positional effects rather than intrinsic reactivi-
ties appear to have a more dominant effect on the observed
[3H]DAF labeling pattern. For example in a-M4 there is an
approximately 3-fold difference in the efficiency of incorpora-
tion between aCys-412 (3.7 cpm/pmol) and aCys-418 (1.2 cpm/
pmol), and incorporation into bTyr-441 (1.3 cpm/pmol), the
residue equivalent to aCys-412, is 3-fold higher than that of
bCys-447 (;0.4 cpm/pmol), the position equivalent to aCys-
418, even though cysteine is likely to have substantially
greater intrinsic reactivity than tyrosine. Within g- and d-sub-
units [3H]DAF incorporation is particularly restricted, with no
incorporation detectable C-terminal to the positions equivalent
to aCys-412. However, the lack of other identifiable labeled
residues in these M4 segments may simply reflect the low level
radiolabeling attainable with [3H]DAF at 1.4 Ci/mmol, and
further studies using [3H]DAF of higher radiochemical specific
activity will be necessary to clarify whether or not residues
such as gPhe-459, gSer-460, or dMet-465 are labeled.
The simplest interpretation of the periodicity of [3H]DAF-
FIG. 10. Radioactivity and mass release upon N-terminal se-
quence analysis of a-K-10K. a-K-10K was isolated by Tricine/SDS-
PAGE (Fig. 9) followed by reversed-phase HPLC (see “Experimental
Procedures”) and then subjected to automated Edman degradation with
60% of each cycle analyzed for released 3H (l, E) and 30% for PTH-
derivatives (M, with the dashed lines corresponding to the exponential
decay fit of the amount of detected PTH-derivatives for the peptides
containing M2). The amino acid sequences of the two primary peptides
that were detected are both shown along the top axis. The sequence of
the primary peptide began at aMet-243 and contained the M2 region,
whereas the secondary sequence began at aTyr-401 and contained M4.
The profile of 3H release is shown for aK-10K labeled in the absence of
agonist (l, 2/2) or in the absence of agonist and in the presence of 100
mM tetracaine (E, 2/1). (2/2 (aMet-243): I0 5 25 pmol; R 5 91%;
(aTyr-401): I0 5 7.8 pmol; R 5 93%; 14,600 cpm loaded/3,500 cpm
remaining on filter after 20 cycles. 2/1 (Met-243): I0 5 25 pmol; R 5
91%; (aTyr-401): I0 5 8.7 pmol; R 5 88%; 15,700 cpm loaded/3,400 cpm
remaining on filter after 20 cycles.)
FIG. 11. Helical representations of
the a-, b-, g-, and d-subunit M4 re-
gions. Helical representations of the a-,
b-, g-, and d-subunit M4 regions.
[3H]DAF-labeled amino acid residues are
indicated along the left side of the helix
along with the location of the labeled
amino acid in the subunit primary se-
quence. Asterisks denote residues that
were previously shown to be labeled by
[125I]TID (16, 17). Helices are oriented
with N termini at the bottom to reflect the
extracellular location of the carboxyl ter-
mini (46).
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labeled residues within the M4 segments of each subunit is
that each of these regions possesses a-helical secondary struc-
ture. Within a-M4 the labeled amino acids would lie on a
broadly defined face of an a-helix distributed over four consec-
utive turns, and when combined with the results for [125I]TID
(17), labeled residues extend over 6 helical turns, spanning a
distance of ;25 Å (Fig. 11). In contrast, the distribution of
[3H]DAF-labeled residues in a-M4 is inconsistent with labeling
of a single face of a b-strand, since three labeled residues
(His-408, Cys-412, and Cys-418) would lie on one face and
Met-415 would lie on the other. Within b-M4, labeled residues
would extend over three helical turns. The limited labeling in
g- and d-M4 precludes assignment of their secondary structure.
Identification of the residues and the corresponding face of
the M4 helices that are in contact with the lipid bilayer pro-
vides an extra measure of importance to several recent struc-
ture-function studies. aCys-418 is labeled nonspecifically by
[125I]TID (16, 17), by [125I]iodonaphthylazide (33), and by
[3H]DAF, and therefore, this position is in all probability ex-
posed to the lipid bilayer. Interestingly, mutation of aCys-418
to tryptophan results in a 28-fold increase in channel open
time, with no effect on channel conductance (34). Similarly,
Bouzat et al. (35) have shown that in the fetal mouse AChR
gLeu-440 and gMet-442 contribute to long duration open chan-
nel events. Both residues are by homology located on the lipid-
exposed face of g-M4, with gLeu-440 equivalent to Torpedo
aCys-412 (as well as to gTrp-453). The obvious implication for
both these studies is that the interactions of regions of the
AChR with the lipid bilayer play an important role in the
determination of the kinetics of channel gating.
Characterization of [3H] DAF Labeling in the Channel—In
the absence of agonist, [3H]DAF labels within M2 segments two
homologous aliphatic residues, bVal-261 and dVal-269. Incor-
poration into these residues is reduced greater than 90% by the
addition of an excess of tetracaine, which binds within the
channel in the absence of agonist (30). Surprisingly, in the
absence of agonist, no [3H]DAF incorporation was detected in
a-M2. It is also striking that the incorporation of [3H]DAF into
dVal-269 occurred five times more efficiently than into bVal-
261. The preferential incorporation into dVal-269 cannot be
easily explained by differences in amino acid side chain reac-
tivities, since a valine is present at that position in all three
subunits (a, b, d). Thus [3H]DAF bound within the ion channel
must be oriented with its photoreactive diazo group facing the
side chain of dVal-269. This selective orientation is then a
consequence of the asymmetry of the [3H]DAF molecule and of
the pore of the ion channel itself. The lack of incorporation into
a-M2 and the less efficient incorporation into b-M2 compared
with d-M2 reflects the arrangement of subunits in the pentam-
eric receptor: a-g-a-d-b (11, 36, 38). Only by determining if
[3H]DAF also reacts with g-M2 can it be determined whether
[3H]DAF can exist in the channel in more than one possible
orientation.
As is illustrated in Fig. 12, the structure of [3H]DAF, the
position of its photoreactive diazo group, and its selective in-
corporation in the absence of agonist into dVal-269 and bVal-
261 are consistent with a constriction in the closed ion channel
located approximately one turn of an a-helix lower at or near
dLeu-265 (position 9). White and Cohen (13) reached essen-
tially this same conclusion based on the incorporation of
[125I]TID into residues at positions 9 and 13 of the M2 region.
Taken together these two reports reinforce this conclusion as
well as the supposition that this restriction might also provide
a barrier to the passage of ions in the closed ion channel.
Further evidence in support of the proposition that a restric-
tion in the channel exists at or around the leucine residues at
position 9 comes from several different investigations. In the
recent three-dimensional structures of the AChR derived from
electron micrographic image analysis, within the transmem-
brane portion of the AChR rod-like structures can be seen
forming the lining of channel pore (4, 12). These rods, which are
interpreted as representing the M2 segments in an a-helical
conformation, are kinked inward toward the central axis at
about their midpoints. Alignment of the three-dimensional
densities (i.e. rods) with the amino acid sequence of M2 sug-
gested that the ring of leucine residues at position 9 project
from the kink and that the association of the leucine side
chains could form a hydrophobic ring, providing a barrier to the
passage of ions. In the presence of agonist, small rotational
motions in the M2 helices would disrupt the association and
allow ion permeation (4). A number of electrophysiological in-
vestigations have focused on the functional consequences of
substitutions of the leucines at position 9. For the a7 neuronal
AChR expressed in oocytes, mutations to several different
amino acids, including serine, result in large leftward shifts of
the dose response for acetylcholine and in a reduction of the
kinetics of desensitization (39). In the muscle-type AChR, for
each leucine to serine mutation the dose response is shifted to
the left by about an order of magnitude (40, 41). Thus, hydro-
phobic interactions between the leucine residues play an im-
portant role in AChR gating (see also Refs. 38 and 42).
A very different model of the structure of the closed channel
results from studies utilizing cysteine-reactive methane thio-
sulfonate derivatives as reactive probes of residues in M2 that
have been mutated to cysteines (43). Since in the absence of
agonist residues lower in the channel than position 9, and even
as low as 21, were still accessible to the probes, it was sug-
gested that the permeability barrier in the closed channel must
be located outside the M2 region. Further studies will be re-
quired to determine unambiguously the permeability barrier to
hydrated Na1 in the closed channel.
In the presence of agonist, [3H]DAF labels a different set of
FIG. 12. Corey-Pauling-Koltun models of the d-M2 helix with
DAF. Corey-Pauling-Koltun helical representation of the d-M2 region
drawn to scale with a (space-filled) DAF molecule. Left, DAF, with its
linear diazo group only approximated (shaded), is shown facing the
dVal-269 side chain labeled by [3H]DAF in the absence of agonist. The
model illustrates that a phenyl ring of diazofluorene (in this orienta-
tion) is approximately in register with dLeu-265, located one turn of an
a-helix lower in the channel than dVal-269. Right, the Corey-Pauling-
Koltun helix is rotated to illustrate dVal-269 labeled by [3H]DAF in the
absence of agonist (resting state) and dSer-262 and dLeu-265 labeled in
the presence of agonist (desensitized state).
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residues in the M2 region. In the a- and d-subunits, a homolo-
gous set of residues are labeled at positions 6 and 9 (aSer-248,
aLeu-251, dSer-262, and dLeu-265), whereas in b-M2 residues
at positions 9 and 10 are labeled (bLeu-257 and bAla-258). It is
striking that the labeling of d-M2 in the presence of agonist
(desensitized state) was 10-fold less efficient than the labeling
in the absence of agonist (Fig. 6). For [125I]TID the agonist-
induced decrease in the effiency of photoincorporation was
observed at positions 9 and 13 in M2 segments of each subunit
(13). For neither probe can this decrease in labeling be simply
attributed to any differences in binding affinity. [125I]TID binds
to the channel with micromolar affinity both in the presence
and absence of agonist (15), and [3H]DAF also inhibits the
binding of [3H]tetracaine in the absence of agonist and [3H]
PCP in the presence of agonist with similar IC50 values (Fig.
1).2 One explanation is that in the presence of agonist, some
molecule near the binding site, perhaps water, is scavenging
the photoactivated species (15, 13). However, in the case of
[3H]DAF, this dramatic agonist-induced decrease in the effi-
ciency of photoincorporation is only observed in d-M2. In b-M2
[3H]DAF photoincorporates into different residues in the two
states but with similar efficiencies. An alternative hypothesis
is that for either [125I]TID or [3H]DAF the efficiency of photo-
incorporation is extremely sensitive to the environment around
the binding site. Subtle differences in the positions of amino
acid side chains that have no net effect on the overall binding
affinity may dramatically effect how the photogenerated reac-
tive carbene inserts. An absence of water in the closed, desen-
sitized channel is also consistent with a characterization of the
molecular environment of the channel as being very hydropho-
bic and with a low dielectric constant (44).
The residues labeled by [3H]DAF in the presence of agonist
would be located one or two turns of an a-helix lower in the
channel than the residues labeled in the absence of agonist.
The redistribution in labeled residues strongly supports previ-
ous observations of an agonist-induced rearrangement of the
M2 helices (13). On the other hand, the redistribution of labeled
residues is relatively small. In fact, residues labeled by
[3H]DAF in the presence of agonist (i.e. dLeu-265 at position 9)
are also strongly labeled by [125I]TID in the absence of agonist
(13). In addition, site-directed mutagenesis experiments reveal
that hydrophobic residues at position 10 of the M2 helix stabi-
lize the binding of QX-222 in the open channel state (45). These
facts taken together suggest that the changes in the structure
of the channel between the closed, open, and desensitized
states may be quite subtle. Gross movements of the M2 helices
such as significant changes in the degree of tilt may be unnec-
essary. Small rotational motions in the helices that serve to
draw the leucine side chains away from the central axis, such
as those proposed by Unwin (4), may better describe the exper-
imental data. In the absence of agonist there is a small amount
of [3H]DAF incorporation into bLeu-257 in b-M2, whereas in
the presence of agonist there is incorporation into bLeu-257
and bAla-258. One interpretation is that this provides evidence
of a small rotational movement in the b-M2 helix between the
resting and desensitized state.
In summary, our results demonstrate that [3H]DAF labels
the channel-forming M2 region of AChR subunits. In the ab-
sence of agonist, [3H]DAF specifically labels homologous ali-
phatic residues at position 13 in the b- and d-subunit M2 region
and does not react with the corresponding Val in a-subunit. In
the presence of agonist, there is a redistribution in the labeled
residues. In a-M2 and d-M2 residues at positions 6 and 9 are
labeled, and in b-M2, residues at positions 9 and 10 are labeled.
The redistribution of labeled residues argues in favor of a
state-dependent rearrangement of the M2 segments (Fig. 12).
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